Discovery of a First-in-Class ANXA3 Degrader for the Treatment of Triple-Negative Breast Cancer

The authors report a first-in-class Annexin A3 (ANXA3)-targeted small molecule (R)-SL18, which demonstrated anti-proliferative and anti-invasive activities to TNBC cells.